#1 Clinical Trials Search in Europe

Omaveloxolone

Omaveloxolone, also known as RTA 408 or SKYCLARYS, is an investigational drug being studied in clinical trials for various conditions, particularly Friedreich’s Ataxia. This article summarizes key information from multiple clinical trials examining the safety, effectiveness, and pharmacokinetics of omaveloxolone in different patient populations.

Table of Contents

What is Omaveloxolone?

Omaveloxolone is a medication that has been developed to treat various conditions, particularly Friedreich’s Ataxia. It is also known by other names such as RTA 408, SKYCLARYS, and BIIB141[1][2]. This drug is part of a class of compounds that work by activating certain cellular pathways involved in reducing inflammation and oxidative stress in the body.

What Conditions Does Omaveloxolone Treat?

Omaveloxolone is primarily used to treat Friedreich’s Ataxia (FA), a rare genetic disorder that affects the nervous system and causes progressive damage to the spinal cord, peripheral nerves, and the brain[2]. It is the first FDA-approved treatment for Friedreich’s Ataxia in patients aged 16 years and older[3].

Additionally, research has been conducted to explore its potential in treating other conditions, including:

  • Advanced solid tumors, particularly non-small cell lung cancer (NSCLC) and melanoma[4]
  • Metastatic or incurable non-small cell lung cancer[4]
  • Relapsed or refractory melanoma[4]

How Does Omaveloxolone Work?

While the exact mechanism of action is complex, omaveloxolone is believed to work by activating a protein called Nrf2. This protein plays a crucial role in protecting cells from oxidative stress and inflammation. By activating Nrf2, omaveloxolone may help to reduce the damage caused by Friedreich’s Ataxia and potentially slow down the progression of the disease[2].

Omaveloxolone in Clinical Trials

Several clinical trials have been conducted or are ongoing to evaluate the safety and effectiveness of omaveloxolone:

  • A study to assess how food affects the absorption of omaveloxolone in healthy volunteers[1]
  • A trial investigating the use of omaveloxolone in children with Friedreich’s Ataxia[2]
  • Research on how omaveloxolone is processed in the body, including its absorption, metabolism, and excretion[5]
  • A study to determine how omaveloxolone affects heart rhythm (QT interval)[6]
  • An investigation into potential drug interactions with omaveloxolone[7]

Dosage and Administration

Omaveloxolone is typically administered orally in capsule form. The dosage can vary depending on the condition being treated and the specific clinical trial. For example:

  • In some studies, doses ranged from 2.5 mg to 150 mg daily[4]
  • For Friedreich’s Ataxia in adults, a dose of 150 mg once daily has been used[1]
  • In children with Friedreich’s Ataxia, dosing is being studied and may be adjusted based on age and other factors[2]

It’s important to note that dosage should always be determined by a healthcare professional based on individual patient factors.

Safety and Side Effects

As with any medication, omaveloxolone may cause side effects. Clinical trials are designed to monitor and assess these effects carefully. Some areas of focus include:

  • General adverse events (AEs) and serious adverse events (SAEs)[3]
  • Potential effects on liver function[3]
  • Possible impacts on heart function, including heart failure[3]
  • Changes in laboratory test results, vital signs, and heart rhythm (ECG)[2]

Patients taking omaveloxolone should report any unusual symptoms or side effects to their healthcare provider promptly.

Omaveloxolone in Special Populations

Research is ongoing to understand how omaveloxolone affects different groups of people:

  • Children with Friedreich’s Ataxia: Studies are being conducted to determine appropriate dosing and safety in children aged 2 to 16 years[2]
  • Pregnant and breastfeeding women: A study is underway to assess how omaveloxolone is transferred into breast milk and its potential effects on infants[8]
  • Pregnancy outcomes: A registry has been established to monitor pregnancy outcomes in women exposed to omaveloxolone during pregnancy[9]

Future Research and Ongoing Studies

Omaveloxolone continues to be the subject of ongoing research to better understand its long-term effects, optimal use, and potential applications in other conditions. Some areas of current investigation include:

  • Long-term safety and effectiveness in patients with Friedreich’s Ataxia[3]
  • Potential use in treating advanced solid tumors, including certain types of lung cancer and melanoma[4]
  • How the body processes and eliminates omaveloxolone[5]
  • Interactions with other medications[7]

As research progresses, our understanding of omaveloxolone and its potential benefits will continue to grow, potentially leading to improved treatments for patients with Friedreich’s Ataxia and other conditions.

Aspect Details
Main Conditions Studied Friedreich’s Ataxia, Advanced Solid Tumors (NSCLC & Melanoma)
Age Groups Adults, Children (2-15 years old)
Administration Oral capsules
Key Study Objectives Safety, Tolerability, Pharmacokinetics, Efficacy
Special Populations Pregnant women, Breastfeeding mothers
Safety Assessments Adverse events, Laboratory tests, ECG, Vital signs
Pharmacokinetic Measures Cmax, AUC, Clearance, Half-life
Long-term Studies Up to 5 years follow-up in some trials

FAQ

  • What is omaveloxolone being studied for? Omaveloxolone is primarily being studied for the treatment of Friedreich's Ataxia. It has also been investigated for advanced solid tumors like non-small cell lung cancer and melanoma.
  • How is omaveloxolone administered? Omaveloxolone is typically administered orally in capsule form. The dosage varies depending on the specific study and condition being treated.
  • What are the main objectives of the omaveloxolone clinical trials? The main objectives include assessing the safety, tolerability, pharmacokinetics (how the drug moves through the body), and effectiveness of omaveloxolone in various patient populations.
  • Are there any studies looking at omaveloxolone use during pregnancy or breastfeeding? Yes, there are observational studies examining the effects of omaveloxolone exposure during pregnancy and lactation to assess potential risks to mothers and infants.
  • What age groups are being studied in omaveloxolone trials? Clinical trials are investigating omaveloxolone in various age groups, including adults and children as young as 2 years old with Friedreich's Ataxia.

Ongoing Clinical Trials on Omaveloxolone

  • A study testing omaveloxolone compared to placebo for children and adolescents aged 2 to 15 years with Friedreich’s ataxia

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany Ireland Italy +2

  • Study to evaluate the effect of omaveloxolone on mitochondrial function in patients with Friedreich’s ataxia

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Poland

  • A Phase 2 Study to Evaluate Safety and Effectiveness of Omaveloxolone (RTA 408) in Patients with Friedreich’s Ataxia

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Italy

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and eliminated.
  • Friedreich's Ataxia (FA): A rare genetic disease that causes progressive damage to the nervous system, resulting in movement problems, heart disease, and other issues.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes significant disability, or is otherwise medically significant.
  • QTc Interval: A measurement on an electrocardiogram that represents the time it takes for the heart's electrical system to recharge between beats, corrected for heart rate.
  • Congenital Malformation: A physical defect present in a baby at birth, which can affect body structure or function.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • CYP3A4: An important enzyme in the body involved in the metabolism of many drugs.

References

  1. https://clinicaltrials.gov/study/NCT03664453
  2. https://clinicaltrials.gov/study/NCT06054893
  3. https://clinicaltrials.gov/study/NCT06623890
  4. https://clinicaltrials.gov/study/NCT02029729
  5. https://clinicaltrials.gov/study/NCT03931590
  6. https://clinicaltrials.gov/study/NCT05927649
  7. https://clinicaltrials.gov/study/NCT05909644
  8. https://clinicaltrials.gov/study/NCT06612879
  9. https://clinicaltrials.gov/study/NCT06628687